Asim Amin

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Jeffrey S. Weber, John A. Thompson, Omid Hamid et al. · Clinical Cancer Research · 2009 · 567 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2017 · 508 citations · Full text

Medicine, Oncology, Pharmacology +17

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Antoni Ribas, Theresa Medina, Shivaani Kummar et al. · Cancer Discovery · 2018 · 341 citations · Full text

Medicine, Immunology, Oncology +17